Cerebrospinal fluid tau and amyloid-β1-42in patients with dementia

The cerebrospinal fluid “Alzheimer profile”: Easily said, but what does it mean?

(2014) Flora H. Duits et al.   Alzheimers & Dementia

Mass Spectrometry-Based Candidate Reference Measurement Procedure for Quantification of Amyloid-  in Cerebrospinal Fluid

(2014) A. Leinenbach et al.   CLINICAL CHEMISTRY

Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease

(2014) Mirjana Babić et al.   CROATIAN MEDICAL JOURNAL

Assessment of CSF Aβ42 as an aid to discriminating Alzheimer's disease from other dementias and mild cognitive impairment: A meta-analysis of 50 studies

(2014) Wei Tang et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

(2014) Bruno Dubois et al.   LANCET NEUROLOGY

CSF A 42 predicts early-onset dementia in Parkinson disease

(2014) G. Alves et al.   NEUROLOGY

A Systematic Review of Biomarkers for Disease Progression in Alzheimer's Disease

(2014) David J. M. McGhee et al.   PLoS One

Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42

(2014) Sebastian Palmqvist et al.   JAMA Neurology

CSF biomarker variability in the Alzheimer's Association quality control program

(2013) Niklas Mattsson et al.   Alzheimers & Dementia

Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration

(2013) Carole S. Scherling et al.   ANNALS OF NEUROLOGY

Costs of diagnosing dementia: results from SveDem, the Swedish Dementia Registry

(2013) Anders Wimo et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

Cerebrospinal fluid biomarkers in Alzheimer’s disease, vascular dementia and ischemic stroke patients: a critical analysis

(2013) Lisa Kaerst et al.   JOURNAL OF NEUROLOGY

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

(2013) Clifford R Jack et al.   LANCET NEUROLOGY

Fluid biomarkers in Alzheimer’s disease – current concepts

(2013) Christoffer Rosén et al.   Molecular Neurodegeneration

The Significance of α-Synuclein, Amyloid-β and Tau Pathologies in Parkinson's Disease Progression and Related Dementia

(2013) Yaroslau Compta et al.   Neurodegenerative Diseases

Clinicopathologic differences among patients with behavioral variant frontotemporal dementia

(2013) M. F. Mendez et al.   NEUROLOGY

Characterization of Novel CSF Tau and ptau Biomarkers for Alzheimer’s Disease

(2013) Jere E. Meredith Jr. et al.   PLoS One

Clinical indications for analysis of Alzheimer's disease CSF biomarkers

(2013) S. Engelborghs   REVUE NEUROLOGIQUE

Cerebrospinal fluid biomarkers for differentiation of frontotemporal lobar degeneration from Alzheimer's disease

(2013) David J. Irwin et al.   Frontiers in Aging Neuroscience

Clinical and multimodal biomarker correlates of ADNI neuropathological findings

(2013) Jon B Toledo et al.   Acta Neuropathologica Communications

CSF biomarkers cutoffs: the importance of coincident neuropathological diseases

(2012) Jon B. Toledo et al.   ACTA NEUROPATHOLOGICA

Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium

(2012) Maria C. Carrillo et al.   Alzheimers & Dementia

Epidemiology of Dementias and Alzheimer’s Disease

(2012) Ana Luisa Sosa-Ortiz et al.   ARCHIVES OF MEDICAL RESEARCH

Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders

(2012) Sara Hall et al.   ARCHIVES OF NEUROLOGY

Dementia Diagnosis Differs in Men and Women and Depends on Age and Dementia Severity: Data from SveDem, the Swedish Dementia Quality Registry

(2012) Dorota Religa et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia

(2012) S. Sorbi et al.   EUROPEAN JOURNAL OF NEUROLOGY

The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers

(2011) Niklas Mattsson et al.   Alzheimers & Dementia

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

Tau and p-tau as CSF biomarkers in dementia: a meta-analysis

(2011) Argonde C. van Harten et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Funcionamiento diferencial de los ítems del test Mini-mental en función de la patología

(2011) G. Prieto et al.   NEUROLOGIA

Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort

(2011) N. S. M. Schoonenboom et al.   NEUROLOGY

Dementia associated with Parkinson’s disease: Applying the Movement Disorder Society Task Force criteria

(2011) P. Martinez-Martin et al.   PARKINSONISM & RELATED DISORDERS

Differential levels of  -synuclein,  -amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease

(2010) K. Kasuga et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

(2010) Kaj Blennow et al.   Nature Reviews Neurology

Diagnostic Value of CSF Biomarker Profile in Frontotemporal Lobar Degeneration

(2009) Elisabeth Kapaki et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

Practical suggestions on how to differentiate dementia with Lewy bodies from Alzheimer's disease with common cognitive tests

(2009) Sebastian Palmqvist et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment

(2009) Niklas Mattsson   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

CSF biomarkers in relationship to cognitive profiles in Alzheimer disease

(2009) A. E. van der Vlies et al.   NEUROLOGY